The 50-day moving average for CSTL moved above the 200-day moving average on September 15, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where CSTL advanced for three days, in 228 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
CSTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 202 of 227 cases where CSTL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
The 10-day RSI Indicator for CSTL moved out of overbought territory on September 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 24 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CSTL as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for CSTL turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 32 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
CSTL moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CSTL crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CSTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.091) is normal, around the industry mean (63.909). P/E Ratio (-50.258) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.947) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. CSTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CSTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
It is expected that a price bounce should occur soon.
Following a +1.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where FEMY advanced for three days, in 152 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
FEMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for FEMY turned negative on September 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 41 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FEMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FEMY entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.387) is normal, around the industry mean (4.887). P/E Ratio (-0.599) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (3.324) is also within normal values, averaging (56.074).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. FEMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FEMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
CSTL | ||
|---|---|---|
OUTLOOK RATING 1..100 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 92 | |
PRICE GROWTH RATING 1..100 | 50 | |
P/E GROWTH RATING 1..100 | 80 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CSTL | FEMY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 87% | N/A |
| Momentum ODDS (%) | 1 day ago 82% | N/A |
| MACD ODDS (%) | 1 day ago 89% | 7 days ago 90% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Advances ODDS (%) | 6 days ago 78% | 28 days ago 82% |
| Declines ODDS (%) | 14 days ago 80% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CSTL’s FA Score shows that 1 FA rating(s) are green while FEMY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CSTL’s TA Score shows that 5 TA indicator(s) are bullish while FEMY’s TA Score has 3 bullish TA indicator(s).
CSTL (@Medical Specialties) experienced а -1.82% price change this week, while FEMY (@Pharmaceuticals: Other) price change was -6.86% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.13%. For the same industry, the average monthly price growth was -3.81%, and the average quarterly price growth was +45.43%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.50%. For the same industry, the average monthly price growth was -2.91%, and the average quarterly price growth was +7.01%.
CSTL is expected to report earnings on Nov 05, 2026.
FEMY is expected to report earnings on Nov 17, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+0.50% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
A.I.dvisor tells us that FEMY and OFIX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FEMY and OFIX's prices will move in lockstep.
| Ticker / NAME | Correlation To FEMY | 1D Price Change % | ||
|---|---|---|---|---|
| FEMY | 100% | -1.21% | ||
| OFIX - FEMY | 30% Poorly correlated | +2.24% | ||
| CSTL - FEMY | 30% Poorly correlated | +0.64% | ||
| LUCD - FEMY | 30% Poorly correlated | -21.05% | ||
| OM - FEMY | 29% Poorly correlated | -3.55% | ||
| GH - FEMY | 29% Poorly correlated | -0.45% | ||
More | ||||